Are there any clinical scenarios in which you would treat BRCA mutated HER2 negative metastatic breast cancer with a PARP inhibitor in combination with carboplatin?

Do any studies support this rationale? Does the presence of a somatic vs germline BRCA mutation impact your decision?

Answer from: Medical Oncologist at Academic Institution

There is a large prospective phase III study that showed a significant improvement in DFS for veliparib+carbo+ paclitaxel versus carbo+paclitaxel (BROCADE3 study; Dieras V et., PMID 32861273).

Comments

Medical Oncologist at Onc San Antonio
Thank you, Dr. @Banu Arun. If I can ask her...

Please select the option that best describes you:

Are there any clinical scenarios in which you would treat BRCA mutated HER2 negative metastatic breast cancer with a PARP inhibitor in combination with carboplatin?

Related Questions